Curcuminoids and resveratrol as anti-Alzheimer agents

Taiwanese Journal of Obstetrics and Gynecology

Volumn 51, Issue 4, 2012, Pages 515-525

  Villaflores, Oliver B ^a   Chen, Ying Ju ^a   Chen, Chih Ping ^b,c,d,e   Yeh, Jui Ming ^a   Wu, Tzong Yuan ^a  

^a CHUNG YUAN CHRISTIAN UNIVERSITY   (Taiwan)

^b MACKAY MEMORIAL HOSPITAL   (Taiwan)

^c ASIA UNIVERSITY   (Taiwan)

^d CHINA MEDICAL UNIVERSITY   (Taiwan)

^e NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

Alzheimer's disease; Amyloid ; Curcuminoids; Resveratrol; Tau hyperphosphorylation

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; ANTIINFLAMMATORY AGENT; COMPLEMENTARY DNA; CURCUMIN; CURCUMINOID DERIVATIVE; CYCLIN DEPENDENT KINASE 2; DEMETHOXYCURCUMIN; DIDEMETHOXYCURCUMIN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FLAVONOID; GLYCOGEN SYNTHASE KINASE 3; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MONODEMETHOXYCURCUMIN; PARAHYDROXYCURCUMIN; POSTSYNAPTIC DENSITY PROTEIN 95; PROTEIN KINASE C; RESVERATROL; SIRTUIN; SIRTUIN 1; SODIUM CALCIUM EXCHANGE PROTEIN; STAT1 PROTEIN; STAT3 PROTEIN; TAU PROTEIN; TOLL LIKE RECEPTOR 4; TRANSCRIPTION FACTOR FOXO; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AGING; ALZHEIMER DISEASE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; BRAIN; CENTRAL NERVOUS SYSTEM; COGNITION; COGNITIVE DEFECT; COMPLEX FORMATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG MECHANISM; EMOTIONAL DISORDER; HIPPOCAMPUS; HUMAN; MULTIPLE SCLEROSIS; NERVE CELL NECROSIS; NEUROFIBRILLARY TANGLE; NEUROPATHOLOGY; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOGENESIS; PATHOPHYSIOLOGY; PREVALENCE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION; SOCIETY; SYMPTOM;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; ANTIOXIDANTS; CURCUMIN; HUMANS; MALE; STILBENES; TAU PROTEINS;

EID: 84871717940     PISSN: 10284559     EISSN: 18756263     Source Type: Journal    
DOI: 10.1016/j.tjog.2012.09.005     Document Type: Review

References (121)

1. Whitehouse P.J., Price D.L., Clark A.W., Coyle J.T., De Long M.R. Alzheimer's disease: evidence for selective loss of cholinergic neurons in the nucleus basalis. Ann Neurol 1981, 10:122-126.
2. Bouchard R.W., Rossor M.N. Typical clinical features. Clinical diagnosis and management of Alzheimer's disease 2006, 39-52. 3rd ed. S. Gauthier (Ed.).
3. Kwok J.B.J., Taddei K., Hallupp M., Fisher C., Brooks W.S., Broe G.A., et al. Two novel (M233T and [rho]278T) presenilin-1 mutations in early-onset Alzheimer's disease pedigrees and preliminary evidence for association of presenilin-1 mutations with a novel phenotype. Neuroreport 1997, 8:1537-1542.
4. Möller H.J., Graeber M.B. The case described by Alois Alzheimer in 1911. Eur Arch Psychiatry Clin Neurosci 1998, 248:111-122.
5. Alzheimer A. über eine eigenartige Erkrankung der Hirnrinde. Allgemeine Zeitschrift fuer Psychiatrie und psychisch-gerichtliche Medicin 1907, 64:146-148.
6. Small D.H., Cappai R. Alois Alzheimer and Alzheimer's disease: a centennial perspective. J Neurochem 2006, 99:708-710.
7. Ferri C.P., Prince M., Brayne C., Brodaty H., Fratiglioni L., Ganguli M., et al. Global prevalence of dementia: a Delphi consensus study. Lancet 2005, 366:2112-2117.
8. WHO Alzheimer's disease: The Brain Killer. [14.02.12]. http://www.searo.who.int/en/Section1174/Section1199/Section1567/Section1823_8066.htm.
9. Dias A., Patel V. Closing the treatment gap for dementia in India. Indian J Psych 2009, 51:93-97.
10. Lewis J., Dickson D.W., Lin W.L., Chisholm L., Corral A., Jones G., et al. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science 2001, 293:1487-1491.
11. Kang J., Lemaire H.G., Unterbeck A., Salbaum J.M., Masters C.L., Grzeschik K.H., et al. The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature 1987, 325:733-736.
12. Yankner B.A., Duffy L.K., Kirschner D.A. Neurotrophic and neurotoxic effects of amyloid beta protein: reversal by tachykinin neuropeptides. Science 1990, 250:279-282.
13. Hartley D.M., Walsh D.M., Ye C.P., Diehl T., Vasquez S., Vassilev P.M., et al. Protofibrillar intermediates of amyloid beta-protein induce acute electrophysiological changes and progressive neurotoxicity in cortical neurons. J Neurosci 1999, 19:8876-8884.
14. Lambert M.P., Barlow A.K., Chromy B.A., Edwards C., Freed R., Liosatos M., et al. Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci U S A 1998, 95:6448-6453.
15. Walsh D.M., Klyubin I., Fadeeva J.V., Cullen W.K., Anwyl R., Wolfe M.S., et al. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 2002, 416:535-539.
16. Ono K., Condron M.M., Teplow D.B. Structure-neurotoxicity relationships of amyloid β-protein oligomers. Proc Natl Acad Sci 2009, 106:14745-14750.
17. Podlisny M.B., Ostaszewski B.L., Squazzo S.L., Koo E.H., Rydell R.E., Teplow D.B., et al. Aggregation of secreted amyloid beta-protein into sodium dodecyl sulfate-stable oligomers in cell culture. J Biol Chem 1995, 270:9564-9570.
18. Walsh D.M., Tseng B.P., Rydel R.E., Podlisny M.B., Selkoe D.J. The oligomerization of amyloid beta-protein begins intracellularly in cells derived from human brain. Biochemistry 2000, 39:10831-10839.
19. Turner R.S., Suzuki N., Chyung A.S., Younkin S.G., Lee V.M. Amyloids beta40 and beta42 are generated intracellularly in cultured human neurons and their secretion increases with maturation. J Biol Chem 1996, 271:8966-8970.
20. Coughlan C.M., Breen K.C. Factors influencing the processing and function of the amyloid β precursor protein-a potential therapeutic target in Alzheimer's disease?. Pharmacol Therapeut 2000, 86:111-144.
21. Jarrett J.T., Lansbury P.T. Seeding "one-dimensional crystallization" of amyloid: a pathogenic mechanism in Alzheimer's disease and scrapie?. Cell 1993, 73:1055-1058.
22. Lansbury P.T. Consequences of the molecular mechanism of amyloid formation for the understanding of the pathogenesis of Alzheimer's disease and the development of therapeutic strategies. Arzneimittelforschung 1995, 45:432-434.
23. Suzuki N., Cheung T.T., Cai X.D., Odaka A., Otvos L., Eckman C., et al. An increased percentage of long amyloid beta protein secreted by familial amyloid beta protein precursor (beta APP717) mutants. Science 1994, 264:1336-1340.
24. Scheuner D., Eckman C., Jensen M., Song X., Citron M., Suzuki N., et al. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat Med 1996, 2:864-870.
25. Goate A., Chartier-Harlin M.C., Mullan M., Brown J., Crawford F., Fidani L., et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 1991, 349:704-706.
26. Breen K.C. APP-collagen interaction is mediated by a heparin bridge mechanism. Mol Chem Neuropathol 1992, 16:109-121.
27. Kibbey M.C., Jucker M., Weeks B.S., Neve R.L., Van Nostrand W.E., Kleinman H.K. Beta-Amyloid precursor protein binds to the neurite-promoting IKVAV site of laminin. Proc Natl Acad Sci U S A 1993, 90:10150-10153.
28. Narindrasorasak S., Altman R.A., Gonzalez-DeWhitt P., Greenberg B.D., Kisilevsky R. An interaction between basement membrane and Alzheimer amyloid precursor proteins suggests a role in the pathogenesis of Alzheimer's disease. Lab Invest 1995, 72:272-282.
29. Coulson E.J., Barrett G.L., Storey E., Bartlett P.F., Beyreuther K., Masters C.L. Down-regulation of the amyloid protein precursor of Alzheimer's disease by antisense oligonucleotides reduces neuronal adhesion to specific substrata. Brain Res 1997, 770:72-80.
30. Multhaup G. Identification and regulation of the high affinity binding site of the Alzheimer's disease amyloid protein precursor (APP) to glycosaminoglycans. Biochimie 1994, 76:304-311.
31. Sisodia S.S., Gallagher M. A role for the beta-amyloid precursor protein in memory?. Proc Natl Acad Sci U S A 1998, 95:12074-12076.
32. Moser E.I., Krobert K.A., Moser M.B., Morris R.G. Impaired spatial learning after saturation of long-term potentiation. Science 1998, 281:2038-2042.
33. Mattson M.P., Cheng B., Culwell A.R., Esch F.S., Lieberburg I., Rydel R.E. Evidence for excitoprotective and intraneuronal calcium-regulating roles for secreted forms of the beta-amyloid precursor protein. Neuron 1993, 10:243-254.
34. Goodman Y., Mattson M.P. Secreted forms of beta-amyloid precursor protein protect hippocampal neurons against amyloid beta-peptide-induced oxidative injury. Exp Neurol 1994, 128:1-12.
35. Jin L.W., Ninomiya H., Roch J.M., Schubert D., Masliah E., Otero D.A., et al. Peptides containing the RERMS sequence of amyloid beta/A4 protein precursor bind cell surface and promote neurite extension. J Neurosci 1994, 14:5461-5470.
36. Pike C.J., Overman M.J., Cotman C.W. Amino-terminal deletions enhance aggregation of beta-amyloid peptides in vitro. J Biol Chem 1995, 270:23895-23898.
37. Kim S.H., Suh Y.H. Neurotoxicity of a carboxyl-terminal fragment of the Alzheimer's amyloid precursor protein. J Neurochem 1996, 67:1172-1182.
38. Kim H.S., Park C.H., Suh Y.H. C-terminal fragment of amyloid precursor protein inhibits calcium uptake into rat brain microsomes by Mg2+-Ca2+ ATPase. Neuroreport 1998, 9:3875-3879.
39. Kim H.S., Lee J.H., Suh Y.H. C-terminal fragment of Alzheimer's amyloid precursor protein inhibits sodium/calcium exchanger activity in SK-N-SH cell. Neuroreport 1999, 10:113-116.
40. Kammesheidt A., Boyce F.M., Spanoyannis A.F., Cummings B.J., Ortegon M., Cotman C., et al. Deposition of beta/A4 immunoreactivity and neuronal pathology in transgenic mice expressing the carboxyl-terminal fragment of the Alzheimer amyloid precursor in the brain. Proc Natl Acad Sci U S A 1992, 89:10857-10861.
41. Pascale A., Bhagavan S., Nelson T.J., Neve R.L., McPhie D.L., Etcheberrigaray R. Enhanced BK-induced calcium responsiveness in PC12 cells expressing the C100 fragment of the amyloid precursor protein. Mol Brain Res 1999, 72:205-213.
42. Cleveland D.W., Hwo S.Y., Kirschner M.W. Purification of tau, a microtubule-associated protein that induces assembly of microtubules from purified tubulin. J Mol Biol 1977, 116:207-225.
43. Cleveland D.W., Hwo S.Y., Kirschner M.W. Physical and chemical properties of purified tau factor and the role of tau in microtubule assembly. J Mol Biol 1977, 116:227-247.
44. Fellous A., Francon J., Lennon A.M., Nunez J. Microtubule assembly in vitro. Purification of assembly-promoting factors. Eur J Biochem 1977, 78:167-174.
45. Binder L.I., Frankfurter A., Rebhun L.I. The distribution of tau in the mammalian central nervous system. J Cell Biol 1985, 101:1371-1378.
46. LoPresti P., Szuchet S., Papasozomenos S.C., Zinkowski R.P., Binder L.I. Functional implications for the microtubule-associated protein tau: localization in oligodendrocytes. Proc Natl Acad Sci U S A 1995, 92:10369-10373.
47. Pittman A.M., Fung H.-C., de Silva R. Untangling the tau gene association with neurodegenerative disorders. Hum Mol Gen 2006, 15:R188-R195.
48. Kanemaru K., Takio K., Miura R., Titani K., Ihara Y. Fetal-type phosphorylation of the tau in paired helical filaments. J Neurochem 1992, 58:1667-1675.
49. Lee G., Cowan N., Kirschner M. The primary structure and heterogeneity of tau protein from mouse brain. Science 1988, 239:285-288.
50. Nelson P.T., Stefansson K., Gulcher J., Saper C.B. Molecular evolution of tau protein: implications for Alzheimer's disease. J Neurochem 1996, 67:1622-1632.
51. Yoshida H., Goedert M. Molecular cloning and functional characterization of chicken brain tau: isoforms with up to five tandem repeats. Biochemistry 2002, 41:15203-15211.
52. Himmler A., Drechsel D., Kirschner M.W., Martin D.W. Tau consists of a set of proteins with repeated C-terminal microtubule-binding domains and variable N-terminal domains. Mol Cell Biol 1989, 9:1381-1388.
53. Goedert M., Spillantini M.G., Cairns N.J., Crowther R.A. Tau proteins of Alzheimer paired helical filaments: abnormal phosphorylation of all six brain isoforms. Neuron 1992, 8:159-168.
54. Goedert M., Spillantini M.G., Potier M.C., Ulrich J., Crowther R.A. Cloning and sequencing of the cDNA encoding an isoform of microtubule-associated protein tau containing four tandem repeats: differential expression of tau protein mRNAs in human brain. EMBO J 1989, 8:393-399.
55. Neve R.L., Harris P., Kosik K.S., Kurnit D.M., Donlon T.A. Identification of cDNA clones for the human microtubule-associated protein tau and chromosomal localization of the genes for tau and microtubule-associated protein 2. Brain Res 1986, 387:271-280.
56. Andreadis A., Broderick J.A., Kosik K.S. Relative exon affinities and suboptimal splice site signals lead to non-equivalence of two cassette exons. Nucleic Acids Res 1995, 23:3585-3593.
57. Buee L., Bussiere T., Buee-Scherrer V., Delacourte A., Hof P.R. Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res Brain Res Rev 2000, 33:95-130.
58. Wang J.-Z., Liu F. Microtubule-associated protein tau in development, degeneration and protection of neurons. Prog Neurobiol 2008, 85:148-175.
59. Martin L., Latypova X., Terro F. Post-translational modifications of tau protein: implications for Alzheimer's disease. Neurochemistry Int 2011, 58:458-471.
60. Khatoon S., Grundke-Iqbal I., Iqbal K. Levels of normal and abnormally phosphorylated tau in different cellular and regional compartments of Alzheimer disease and control brains. FEBS Lett 1994, 351:80-84.
61. Khatoon S., Grundke-Iqbal I., Iqbal K. Brain levels of microtubule-associated protein tau are elevated in Alzheimer's disease: a radioimmuno-slot-blot assay for nanograms of the protein. J Neurochem 1992, 59:750-753.
62. Yaffe M.B., Schutkowski M., Shen M., Zhou X.Z., Stukenberg P.T., Rahfeld J.U., et al. Sequence-specific and phosphorylation-dependent proline isomerization: a potential mitotic regulatory mechanism. Science 1997, 278:1957-1960.
63. Yotsumoto K., Saito T., Asada A., Oikawa T., Kimura T., Uchida C., et al. Effect of Pin1 or microtubule binding on dephosphorylation of FTDP-17 mutant Tau. J Biol Chem 2009, 284:16840-16847.
64. Reyes J.F., Reynolds M.R., Horowitz P.M., Fu Y., Guillozet-Bongaarts A.L., Berry R., et al. A possible link between astrocyte activation and tau nitration in Alzheimer's disease. Neurobiol Dis 2008, 31:198-208.
65. Reynolds M.R., Berry R.W., Binder L.I. Site-specific nitration differentially influences tau assembly in vitro. Biochemistry 2005, 44:13997-14009.
66. Horiguchi T., Uryu K., Giasson B.I., Ischiropoulos H., LightFoot R., Bellmann C., et al. Nitration of tau protein is linked to neurodegeneration in tauopathies. Am J Pathol 2003, 163:1021-1031.
67. Wang D.S., Dickson D.W., Malter J.S. Tissue transglutaminase, protein cross-linking and Alzheimer's disease: review and views. Int J Clin Exp Pathol 2008, 1:5-18.
68. Murthy S.N., Wilson J.H., Lukas T.J., Kuret J., Lorand L. Cross-linking sites of the human tau protein, probed by reactions with human transglutaminase. J Neurochem 1998, 71:2607-2614.
69. Schweers O., Mandelkow E.M., Biernat J., Mandelkow E. Oxidation of cysteine-322 in the repeat domain of microtubule-associated protein tau controls the in vitro assembly of paired helical filaments. Proc Natl Acad Sci U S A 1995, 92:8463-8467.
70. Landino L.M., Skreslet T.E., Alston J.A. Cysteine oxidation of tau and microtubule-associated protein-2 by peroxynitrite: modulation of microtubule assembly kinetics by the thioredoxin reductase system. J Biol Chem 2004, 279:35101-35105.
71. Allain H., Bentue-Ferrer D., Tribut O., Gauthier S., Michel B.F., Drieu-La Rochelle C. Alzheimer's disease: the pharmacological pathway. Fundam Clin Pharmacol 2003, 17:419-428.
72. Stafford G.I., Pedersen M.E., van Staden J., Jager A.K. Review on plants with CNS-effects used in traditional South African medicine against mental diseases. J Ethnopharmacol 2008, 119:513-537.
73. Howes M.J., Houghton P.J. Plants used in Chinese and Indian traditional medicine for improvement of memory and cognitive function. Pharmacol Biochem Behav 2003, 75:513-527.
74. Raskin I., Ribnicky D.M., Komarnytsky S., Ilic N., Poulev A., Borisjuk N., et al. Plants and human health in the twenty-first century. Trends Biotechnol 2002, 20:522-531.
75. Miłobe{ogonek}dzka J., Kostanecki S., Lampe V. Zur Kenntnis des Curcumins. Berichte der deutschen chemischen Gesellschaft 1910, 43:2163-2170.
76. Srivastava R., Dikshit M., Srimal R.C., Dhawan B.N. Anti-thrombotic effect of curcumin. Thromb Res 1985, 40:413-417.
77. Abe Y., Hashimoto S.H.U., Horie T. Curcumin inhibition inflammatory cytokine production by human peripheral blood monocytes and alveolar macrophages. Pharmacol Res 1999, 39:41-47.
78. Sharma O.P. Antioxidant activity of curcumin and related compounds. Biochem Pharmacol 1976, 25:1811-1812.
79. Adams B.K., Ferstl E.M., Davis M.C., Herold M., Kurtkaya S., Camalier R.F., et al. Synthesis and biological evaluation of novel curcumin analogs as anti-cancer and anti-angiogenesis agents. Bioorg Med Chem 2004, 12:3871-3883.
80. Sidhu G.S., Singh A.K., Thaloor D., Banaudha K.K., Patnaik G.K., Srimal R.C., et al. Enhancement of wound healing by curcumin in animals. Wound Repair Regen 1998, 6:167-177.
81. Lim G.P., Chu T., Yang F., Beech W., Frautschy S.A., Cole G.M. The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. J Neurosci 2001, 21:8370-8377.
82. Natarajan C., Bright J.J. Curcumin inhibits experimental allergic encephalomyelitis by blocking IL-12 signaling through Janus kinase-STAT pathway in T lymphocytes. J Immunol 2002, 168:6506-6513.
83. Zbarsky V., Datla K.P., Parkar S., Rai D.K., Aruoma O.I., Dexter D.T. Neuroprotective properties of the natural phenolic antioxidants curcumin and naringenin but not quercetin and fisetin in a 6-OHDA model of Parkinson's disease. Free Radic Res 2005, 39:1119-1125.
84. Sumanont Y., Murakami Y., Tohda M., Vajragupta O., Watanabe H., Matsumoto K. Prevention of kainic acid-induced changes in nitric oxide level and neuronal cell damage in the rat hippocampus by manganese complexes of curcumin and diacetylcurcumin. Life Sci 2006, 78:1884-1891.
85. Ghoneim A.I., Abdel-Naim A.B., Khalifa A.E., El-Denshary E.S. Protective effects of curcumin against ischaemia/reperfusion insult in rat forebrain. Pharmacol Res 2002, 46:273-279.
86. Calabrese V., Scapagnini G., Colombrita C., Ravagna A., Pennisi G., Giuffrida Stella A.M., et al. Redox regulation of heat shock protein expression in aging and neurodegenerative disorders associated with oxidative stress: a nutritional approach. Amino Acids 2003, 25:437-444.
87. Bishnoi M., Chopra K., Kulkarni S.K. Protective effect of Curcumin, the active principle of turmeric (Curcuma longa) in haloperidol-induced orofacial dyskinesia and associated behavioural, biochemical and neurochemical changes in rat brain. Pharmacol Biochem Behav 2008, 88:511-522.
88. Hafner-Bratkovic I., Gaspersic J., Smid L.M., Bresjanac M., Jerala R. Curcumin binds to the alpha-helical intermediate and to the amyloid form of prion protein - a new mechanism for the inhibition of PrP(Sc) accumulation. J Neurochem 2008, 104:1553-1564.
89. Sharma S., Kulkarni S.K., Agrewala J.N., Chopra K. Curcumin attenuates thermal hyperalgesia in a diabetic mouse model of neuropathic pain. Eur J Pharmacol 2006, 536:256-261.
90. Xu Y., Ku B.S., Yao H.Y., Lin Y.H., Ma X., Zhang Y.H., et al. The effects of curcumin on depressive-like behaviors in mice. Eur J Pharmacol 2005, 518:40-46.
91. Smith D.G., Cappai R., Barnham K.J. The redox chemistry of the Alzheimer's disease amyloid beta peptide. Biochim Biophys Acta 2007, 1768:1976-1990.
92. Huang H.-C., Lin C.-J., Liu W.-J., Jiang Z- F. Dual effects of curcumin on neuronal oxidative stress in the presence of Cu(II). Food Chem Toxicol 2011, 49:1578-1583.
93. Kim D.S., Park S.Y., Kim J.K. Curcuminoids from Curcuma longa L. (Zingiberaceae) that protect PC12 rat pheochromocytoma and normal human umbilical vein endothelial cells from betaA(1-42) insult. Neurosci Lett 2001, 303:57-61.
94. Zhang C., Browne A., Child D., Tanzi R.E. Curcumin decreases amyloid-beta peptide levels by attenuating the maturation of amyloid-beta precursor protein. J Biol Chem 2010, 285:28472-28480.
95. Ishrat T., Hoda M.N., Khan M.B., Yousuf S., Ahmad M., Khan M.M., et al. Amelioration of cognitive deficits and neurodegeneration by curcumin in rat model of sporadic dementia of Alzheimer's type (SDAT). Eur Neuropsychopharmacol 2009, 19:636-647.
96. Yang F., Lim G.P., Begum A.N., Ubeda O.J., Simmons M.R., Ambegaokar S.S., et al. Curcumin inhibits formation of amyloid-beta oligomers and fibrils, binds plaques and reduces amyloid in vivo. J Biol Chem 2005, 280:5892-5901.
97. Yanagisawa D., Shirai N., Amatsubo T., Taguchi H., Hirao K., Urushitani M., et al. Relationship between the tautomeric structures of curcumin derivatives and their Aβ-binding activities in the context of therapies for Alzheimer's disease. Biomaterials 2010, 31:4179-4185.
98. Reinke A.A., Gestwicki J.E. Structure-activity relationships of amyloid beta-aggregation inhibitors based on curcumin: influence of linker length and flexibility. Chem Biol Drug Des 2007, 0:206-215.
99. Johnson G.V., Jope R.S. The role of microtubule-associated protein 2 (MAP-2) in neuronal growth, plasticity, and degeneration. J Neurosci Res 1992, 33:505-512.
100. Xiao Z., Lin L., Liu Z., Ji F., Shao W., Wang M., et al. Potential therapeutic effects of curcumin: relationship to microtubule associated proteins 2 in Ab 1-2 insults. Brain Res 2010, 1361:115-123.
101. Masuda T., Hidaka K., Shinohara A., Maekawa T., Takeda Y., Yamaguchi H. Chemical studies on antioxidant mechanism of curcuminoid: analysis of radical reaction products from curcumin. J Agric Food Chem 1999, 47:71-77.
102. Masuda Y., Fukuchi M., Yatagawa T., Tada M., Takeda K., Irie K., et al. Solid-state NMR analysis of interaction sites of curcumin and 42-residue amyloid β-protein fibrils. Bioorg Med Chem 2011, 19:5967-5974.
103. Liu H., Li Z., Qiu D., Gu Q., Lei Q., Mao L. The inhibitory effects of different curcuminoids on β-amyloid protein, β-amyloid precursor protein and β-site amyloid precursor protein cleaving enzyme 1 in swAPP HEK293 cells. Neurosci Lett 2010, 485:83-88.
104. Kim D.S.H.L., Park S.-Y., Kim J.-Y. Curcuminoids from Curcuma longa L. (Zingiberaceae) that protect PC12 rat pheochromocytoma and normal human umbilical vein endothelial cells from βA(1-42) insult. Neurosci Lett 2001, 303:57-61.
105. Ahmed T., Gilani A.-H. Inhibitory effect of curcuminoids on acetylcholinesterase activity and attenuation of scopolamine-induced amnesia may explain medicinal use of turmeric in Alzheimer's disease. Pharmacol Biochem Behav 2009, 91:554-559.
106. Takaoka M. Resveratrol, a new phenolic compound from Veratrum grandiflorum. Nippon Kagaku Kaishi 1939, 60:1090-1100.
107. Lamuela-Raventos R.M., Romero-Perez A.I., Waterhouse A.L., de la Torre-Boronat M.C. Direct HPLC analysis of cis- and trans-resveratrol and piceid isomers in Spanish red Vitis vinifera wines. J Agric Food Chem 1995, 43:281-283.
108. Favaron F., Odorizzi S., Pais da Cunha A.T., Sella L. The role of grape polyphenols on trans-resveratrol activity against Botrytis cinerea and of fungal laccase on the solubility of putative grape PR proteins. J Plant Pathol 2009, 91:579-588.
109. Anekonda T.S. Resveratrol - a boon for treating Alzheimer's disease?. Brain Res Rev 2006, 52:316-326.
110. Baur J.A., Sinclair D.A. Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov 2006, 5:493-506.
111. Anekonda T.S., Reddy P.H. Neuronal protection by sirtuins in Alzheimer's disease. J Neurochem 2006, 96:305-313.
112. Chen J., Zhou Y., Mueller-Steiner S., Chen L.F., Kwon H., Yi S., et al. SIRT1 protects against microglia-dependent amyloid-beta toxicity through inhibiting NF-kappaB signaling. J Biol Chem 2005, 280:40364-40374.
113. Gentile M.T., Vecchione C., Maffei A., Aretini A., Marino G., Poulet R., et al. Mechanisms of soluble beta-amyloid impairment of endothelial function. J Biol Chem 2004, 279:48135-48142.
114. Capiralla H., Vingtdeux V., Zhao H., Sankowski R., Al-Abed Y., Davies P., et al. Resveratrol mitigates lipopolysaccharide- and Aβ-mediated microglial inflammation by inhibiting the TLR4/NF-κB/STAT signaling cascade. J Neurochem 2012, 120:461-472.
115. Reddy P.H., Beal M.F. Are mitochondria critical in the pathogenesis of Alzheimer's disease?. Brain Res Brain Res Rev 2005, 49:618-632.
116. Jang J.H., Surh Y.J. Protective effect of resveratrol on beta-amyloid-induced oxidative PC12 cell death. Free Radic Biol Med 2003, 34:1100-1110.
117. Marambaud P., Zhao H., Davies P. Resveratrol promotes clearance of Alzheimer's disease amyloid-beta peptides. J Biol Chem 2005, 280:37377-37382.
118. de Vrij F.M., Fischer D.F., van Leeuwen F.W., Hol E.M. Protein quality control in Alzheimer's disease by the ubiquitin proteasome system. Prog Neurobiol 2004, 74:249-270.
119. Granzotto A., Zatta P. Resveratrol acts not through anti-aggregative pathways but mainly via its scavenging properties against Abeta and Abeta-metal complexes toxicity. PLoS One 2011, 6:e21565.
120. Karuppagounder S.S., Pinto J.T., Xu H., Chen H.-L., Beal M.F., Gibson G.E. Dietary supplementation with resveratrol reduces plaque pathology in a transgenic model of Alzheimer's disease. Neurochem Int 2009, 54:111-118.
121. Vitaglione P., Sforza S., Galaverna G., Ghidini C., Caporaso N., Vescovi P.P., et al. Bioavailability of trans-resveratrol from red wine in humans. Mol Nutr Food Res 2005, 49:495-504.